Peptide evidence review

What the research actually shows about tesamorelin

Tesamorelin is the rare growth-hormone-releasing peptide that is genuinely FDA-approved and backed by replicated Phase-3 trials — but only for one disease: HIV-associated lipodystrophy. In that population it reduces visceral belly fat by roughly 15 to 18 percent, repeatedly, and a 2026 meta-analysis confirms it. The honest catch is everything the approval leaves out: the effect reverses when you stop, the label itself says it is 'not indicated for weight loss management,' the controlled evidence outside HIV is limited to a few selected research groups, and there is no controlled human trial of tesamorelin for general fat loss, anti-aging, bodybuilding, or performance.

The honest read

Tesamorelin is the rare compound on this site that earns a different opening, and it is worth saying plainly before anything else: it is genuinely FDA-approved, and the approval rests on real evidence. In two large placebo-controlled Phase-3 trials, daily tesamorelin reduced visceral belly fat by roughly fifteen to eighteen percent in HIV patients whose antiretroviral therapy had driven fat into the abdomen, improved their triglycerides, and did so without meaningfully disturbing blood sugar. Those results were replicated, pooled, and confirmed again in a 2026 meta-analysis. This is not a hormone level moving in a handful of volunteers, which is all that stands behind most of its cousins. It is a measured clinical outcome, by imaging, in patients, repeated. When people say tesamorelin "actually works," they are, for once, pointing at something real.

The honest part is everything that sentence leaves out. The approval is narrow: tesamorelin is approved for one disease, HIV-associated lipodystrophy, in one population, at one dose. Its own FDA label says, in as many words, that it is "not indicated for weight loss management" and that its long-term cardiovascular safety has not been established. The fat it removes comes back when you stop, every time, because the effect lasts only as long as the injections do. Outside that approved indication, the evidence thins fast: the only controlled studies in people without HIV were done in carefully selected groups, and there is no controlled human trial of tesamorelin for athletic performance, bodybuilding, recovery, or general anti-aging at all. And because it works by pushing your own growth-hormone and IGF-1 levels up, the label carries real warnings about glucose, fluid retention, and the risk of stimulating tumor growth. This piece does the one thing the marketing will not: it keeps the approved drug and its evidence in one box, the off-label hope in another, and refuses to let the first launder the second.

What tesamorelin is and how it is thought to work

Tesamorelin, sold as EGRIFTA and the reformulated EGRIFTA SV, is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH), the natural signal your hypothalamus uses to tell the pituitary gland to release growth hormone. Like CJC-1295 and sermorelin, it is a secretagogue: rather than supplying growth hormone directly, it prompts your own pituitary to release more of it, which in turn drives the liver to make IGF-1 (Wang and Hu 2009; Spooner and Olin 2012). It is built on the active human GHRH(1-44) sequence and acts at the same receptor.

The difference between tesamorelin and the GHRH analogs sold on the gray market is not chemistry so much as history. Native GHRH lasts only minutes in the blood before enzymes break it down, which makes it useless as a daily injection. Tesamorelin adds a small chemical group to the front of the molecule that slows that breakdown enough to make once-daily subcutaneous dosing viable (Ferdinandi et al. 2007). It does not use the albumin-binding trick that gives CJC-1295 its multi-day duration; it is a short-acting daily injectable. What sets it apart from CJC-1295 and ipamorelin is simply that a company, Theratechnologies, took it through full Phase-3 trials and an FDA approval, and the others were never finished.

Worth keeping straight, because it matters for any dose figure you read: the two pivotal trials and most of the research used 2 mg once daily. The current product, EGRIFTA SV, is a reformulation dosed at 1.4 mg once daily. The one anti-aging-adjacent study used 1 mg. When a clinic page or forum quotes a tesamorelin dose, the version and the indication behind that number both matter, and they are frequently blurred.

What the research actually shows, graded by evidence tier

Here is the split that organizes everything. There is one use of tesamorelin with a genuine, replicated, approved evidence base. There is a second tier of single trials, all preliminary, mostly still in HIV patients, that point in promising directions. And there is a large third category of things tesamorelin is sold for that have no controlled human evidence at all. The strength of the claim collapses as you move down that list, and almost all the off-label demand sits at the bottom.

Visceral fat in HIV-associated lipodystrophy: the approved, evidenced use

This is the high-water mark, and it is real. In the pivotal Phase-3 trial, 412 HIV patients with abdominal fat accumulation received 2 mg of tesamorelin or placebo daily for 26 weeks; visceral fat measured by CT fell by 15.2 percent in the tesamorelin group and rose 5 percent on placebo, triglycerides dropped by about 50 mg/dL, and IGF-1 rose 81 percent (Falutz et al. 2007). A second Phase-3 trial of 404 patients reproduced the effect, with visceral fat down about 18 percent in those who continued for a full year (Falutz et al. 2010, JAIDS). Pooling both trials at 806 patients, the visceral-fat treatment effect was 15.4 percent at 26 weeks and 17.5 percent at 52 weeks, with improved lipids and body image and no clinically meaningful change in glucose (Falutz et al. 2010, JCEM). A systematic review and, more recently, a 2026 meta-analysis of five tesamorelin trials confirmed the picture: visceral fat down by about 28 cm², hepatic fat and waist circumference reduced, lean body mass up, "without serious side effects or perturbation of glucose" (Sivakumar et al. 2011; Badran et al. 2026). It still works on modern integrase-inhibitor regimens (Russo et al. 2024).

That is what an approved, evidenced peptide looks like, and it is the honest reason tesamorelin is treated differently from its cousins. But two caveats travel with it everywhere. First, all of this is in HIV-associated lipodystrophy, a specific disease state, not in a healthy person trying to lose belly fat. Second, and more important than it sounds: the effect does not last beyond treatment. In the 52-week extension, the authors state it directly. Once tesamorelin is discontinued, the visceral fat reaccumulates, and switching from drug to placebo rapidly erased the gains (Falutz et al. 2008; Falutz et al. 2010, JAIDS). This is an indefinitely continued therapy for a chronic condition, not a course that fixes something. Whatever it costs, in money and in the unknowns of long-term use, it costs that for as long as you want to keep the result.

Liver fat and NAFLD in HIV: promising, still preliminary

The most interesting newer thread is liver fat. In a randomized trial of 50 HIV patients, tesamorelin reduced both visceral fat and liver fat over six months (Stanley et al. 2014). A dedicated 12-month trial in 61 HIV patients with fatty liver disease found a 37 percent relative reduction in liver-fat fraction, and 35 percent of treated patients dropped below the threshold for fatty liver versus 4 percent on placebo (Stanley et al. 2019). The investigators are careful to call this preliminary and to say larger studies are needed, and one detail belongs in front of anyone with glucose concerns: in the liver-fat trial, fasting glucose ticked up by about 7 mg/dL in the first two weeks before settling, a small early signal consistent with the label's glucose warning (Stanley et al. 2014). This is genuine, promising work. It is also still in the HIV population, still in small numbers, and still labeled "further studies needed" by the people who ran it.

Outside HIV: only selected groups, not the general buyer

This is where the off-label market gets ahead of the evidence. The only controlled trials of tesamorelin in people without HIV were done in specifically selected groups, not the general population that buys it. In abdominally obese adults who had been screened to have reduced growth-hormone secretion, a year of tesamorelin reduced visceral fat and improved several cardiovascular markers without worsening glucose (Makimura et al. 2012). In a 20-week trial in older adults with mild cognitive impairment and healthy older adults, tesamorelin at the lower 1 mg dose had a modest favorable effect on cognition, especially executive function, while raising IGF-1 by 117 percent and lowering body fat 7.4 percent, though it also raised fasting insulin by 35 percent in the cognitively impaired group and produced more side effects than placebo (Baker et al. 2012). In type-2 diabetics, a 12-week safety study found it did not worsen glycemic control (Clemmons et al. 2017). And in healthy men, two weeks of tesamorelin raised growth hormone and IGF-1 while leaving insulin-stimulated glucose uptake intact (Stanley et al. 2011).

Read those carefully and the boundary is clear. Each is a selected population (low growth-hormone obesity, cognitive impairment, diabetes, a tiny healthy-male pharmacology study), each is short, and none of them establishes that a hormonally normal adult should expect general fat loss, recomposition, or anti-aging from tesamorelin. The cognition signal is the strongest "anti-aging-adjacent" data the drug has, and it is one 20-week trial at a lower dose that its own authors said needs longer study. The general-population fat-loss and longevity claims do not have a trial behind them; they have a mechanism and an extrapolation.

Performance, bodybuilding, recovery, general anti-aging: not tested

There is no controlled human trial of tesamorelin for athletic performance, muscle building in healthy people, training recovery, or general anti-aging. The case for those uses rests entirely on two things: the IGF-1 number going up, which is real, and the visceral-fat results in HIV patients, which belong to a different population and a disease indication. The leap from "raises IGF-1 and removes belly fat in HIV lipodystrophy" to "will recompose a healthy lifter or slow aging" is exactly the leap the marketing makes and the evidence does not. Sports-medicine reviews place tesamorelin and its GH-axis relatives in the investigational-or-narrowly-approved category for precisely this reason (Mayfield et al. 2026; Rahman et al. 2026).

Safety, the warnings, and what we don't know

Because tesamorelin is an approved drug, its safety profile is far better characterized than any gray-market peptide, and the most important safety content is the label itself. The FDA label carries warnings for increased risk of neoplasms, elevated IGF-1 levels, fluid retention, glucose intolerance or diabetes, hypersensitivity reactions, injection-site reactions, and increased mortality in patients with acute critical illness. It is contraindicated in people with disruption of the hypothalamic-pituitary axis, active malignancy, pregnancy, and known hypersensitivity to the drug.

Two of those deserve to be stated plainly rather than buried. The neoplasm warning exists because tesamorelin works by raising growth hormone and IGF-1, and IGF-1 is a growth signal; the label flags both the elevated IGF-1 itself and the theoretical concern about stimulating tumor growth, which is why active malignancy is a contraindication and a personal or family history of cancer is a serious conversation to have before starting. This is a mechanism-based caution, not a demonstrated cancer link in humans, and it should be carried as exactly that: a real, label-level reason for caution, not proof of harm and not something to wave away. The glucose warning is the other. Across the HIV trials, daily tesamorelin did not clinically worsen glucose over 6 to 12 months, which is genuinely reassuring; but a transient early glucose rise showed up in the liver-fat study, growth hormone antagonizes insulin by mechanism, and the label tells prescribers to monitor glucose. "Did not worsen glucose in the trials" and "glucose-neutral and safe to ignore" are not the same statement.

In the trials themselves, the most common side effects were injection-site reactions, with arthralgia, fluid retention, and the occasional carpal-tunnel-type symptom reflecting the familiar growth-hormone-excess profile (Falutz et al. 2007; Badran et al. 2026). Tesamorelin can also alter how the liver clears other drugs, which matters in a population often taking antiretrovirals and statins; a dedicated study looked at its interaction with simvastatin and ritonavir (Teng et al. 2013).

The part the wellness market omits is that this reassuring safety profile was earned in HIV patients, under monitoring, for the approved indication. It does not automatically describe a hormonally normal adult using tesamorelin off-label for fat loss or anti-aging, frequently without IGF-1 or glucose monitoring, and often from gray-market supply of uncertain identity and purity. When the indication is absent and the benefit unproven, the neoplasm, IGF-1, and glucose warnings apply with more weight, not less. And the label's own admission that long-term cardiovascular safety has not been established is not a small footnote in people who are using the drug precisely because of their cardiometabolic profile.

FDA status and anti-doping (WADA) status

Start with the status, because for once it is the favorable fact and most pages still get the boundaries wrong.

First, FDA status: tesamorelin is genuinely FDA-approved. It was approved in 2010 (as EGRIFTA, now marketed as EGRIFTA SV) for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy (Traynor 2010; FDA EGRIFTA SV label). That is the real approval that distinguishes it from CJC-1295, ipamorelin, and the rest, and it is the example of what "approved and evidenced" actually looks like. But the same label that approves it draws the fence: it states the drug is "not indicated for weight loss management" and that its long-term cardiovascular safety has not been established. Prescribing it off-label, for general fat loss or anti-aging or performance, is legal at a clinician's discretion, but it is off-label by definition: outside the indication, the population, and often the dose that were actually studied and approved.

Second, anti-doping status, which surprises people precisely because the drug is approved. Tesamorelin is named explicitly on the World Anti-Doping Agency Prohibited List, under Section S2, in the growth-hormone-releasing-factors sub-class, alongside CJC-1295 and sermorelin, and it is prohibited at all times, in and out of competition. It is also detectable; it appears as a target analyte in validated anti-doping assays (Thomas et al. 2015). Being an FDA-approved medicine does not change this: an athlete subject to anti-doping rules who uses tesamorelin commits a violation, and the idea that an approved peptide is somehow exempt is false. This belongs in front of anyone who competes.

How and when to think about using tesamorelin

Vague "ask your doctor" is not useful, so here is the specific version, and for tesamorelin it starts with a distinction the gray market erases. There is an approved, evidence-based dose for tesamorelin, but it exists only for one purpose: 2 mg daily (or 1.4 mg of the EGRIFTA SV reformulation) for the reduction of visceral fat in HIV-associated lipodystrophy. For that indication, in that population, the decision is a straightforward clinical one between a patient and an HIV or metabolic specialist, weighing a real benefit against the label's real warnings. We are not going to add anything to that conversation except the reminder that the benefit lasts only as long as treatment.

For every other use, the honest framing is that you are stepping outside the evidence. There is no approved dose for general fat loss, anti-aging, recomposition, or performance, because no trial tested tesamorelin for those goals in people like you, and the FDA label says it is not for weight loss. What the off-label clinics and communities use is a practice pattern, not a validated protocol, and the next section reports it so you can see it clearly rather than from a vendor's pitch. The decision factors are the ones already on this page, lined up. The upside outside HIV lipodystrophy is unproven: real in a disease state, plausible by mechanism elsewhere, demonstrated nowhere in the general population. The effect, even where it is real, reverses when you stop. The safety profile is reassuring for the approved use under monitoring and unestablished for off-label use without it, with a long-term cardiovascular safety gap the label itself admits and IGF-1, glucose, and neoplasm cautions that do not soften because the drug is popular. The supply, if it is not a pharmacy prescription, is unregulated and of uncertain identity. And the sport status is settled and against use.

Some "when not" answers are clear enough to state plainly. If you have an active or prior malignancy, or a strong personal or family history of cancer, chronically raising a growth signal like IGF-1 is exactly the exposure the contraindication and the neoplasm warning exist to prevent. If you are pregnant or might become pregnant, it is contraindicated. If you have a disrupted pituitary axis, a secretagogue has nothing to work with. If you are subject to anti-doping testing, this is a named, detectable, banned substance and the answer is no. If you have diabetes or glucose problems, the label's glucose warning is a reason for caution and monitoring, not a casual decision. And if you cannot verify what is actually in the vial, with a batch-specific certificate of analysis, you are dosing an unknown. If, knowing all of that, the use you are weighing is the approved one, that is a real medical decision with a real evidence base behind it. If it is anything else, you are choosing to be the experiment.

What people and clinics actually do with tesamorelin (and what we can't tell you)

The line that governs everything below: tesamorelin has an approved dose for one disease, and almost everything in this section is the off-label use that goes beyond it. What people and clinics report doing for fat loss, anti-aging, and recomposition has not been validated for those goals, and it is the weakest tier of evidence on this page. We include it because pretending the real-world use does not exist makes no one safer; understanding it, with the risks named, does.

What's commonly reported. Off-label, the most commonly reported dose is not the 2 mg label dose but 1 mg per day, described across community and clinic write-ups as a deliberate reduction from the label "for cost savings or anti-aging applications," with some running the full 1 to 2 mg. It is injected subcutaneously, and the timing people report is borrowed straight from growth-hormone-peptide lore: in the evening, fasted, an hour or two after the last meal, on the theory of aligning with the natural overnight growth-hormone pulse. None of that pre-bed-fasted framing is on the label; it is community pharmacology. To stretch expensive vials, "five days on, two days off" weekly patterns and longer cycles of eight to twenty-six weeks circulate widely, often citing the trial's 26-week endpoint as if it were a cycle length. Read every one of those numbers as practice pattern, not as a tested protocol for these goals.

The stack. The near-universal off-label practice is to combine tesamorelin with ipamorelin, a separate growth-hormone secretagogue, on the same dual-pathway theory used to justify the CJC-1295 and ipamorelin pairing, and increasingly to stack it further with GLP-1 drugs like semaglutide or with testosterone for "recomposition." State this plainly: none of these combinations has been tested in a human trial for the outcomes they are sold for. One of the more prominent stacking sources says so itself, conceding there are no published human trials of the tesamorelin-and-ipamorelin combination, which means any "synergy" figure attached to it is mechanism extrapolation, not measured data.

What the community itself flags. The reported cautions track the label, which is a point in their favor: water retention as the most-mentioned early side effect, usually said to settle after a few weeks; injection-site redness; joint aches and occasional tingling; and rising blood sugar or insulin resistance over time, with monitoring of IGF-1, fasting glucose, and HbA1c widely advised. The IGF-1-and-cancer concern is repeated as a theoretical, mechanism-level caution rather than an established link, which is the correct way to hold it. And the reversibility of the fat loss when you stop is broadly understood.

What we can't tell you, honestly. Several cautions about the numbers above. We could not read the primary forum threads directly, because Reddit blocked automated access on every route we tried, so these figures come second-hand through SEO write-ups that summarize community practice rather than from the threads themselves, and we have invented nothing to fill that gap. The off-label dose figures, the cost-cutting schedules, and the stack ratios come overwhelmingly from peptide vendors, dosing aggregators, and clinics that also sell the product, cross-citing one another, so their apparent agreement is an echo chamber rather than independent confirmation. The most important pattern to watch is the laundering one: clinic and vendor pages quote the genuine 15 percent visceral-fat figure from the HIV trials and then apply it to non-HIV anti-aging patients, as if the disease-population result transferred. It does not. We have left out vendor side-effect percentages that re-state the trial's injection-site numbers without their placebo comparators, and the "reduces belly fat in one to two weeks" claims that contradict a trial whose endpoint was 26 weeks. Read the consistency as the story the market tells itself, not as evidence any of the off-label protocol is right or safe.

If you are going to explore it anyway, the harm-reduction version is straightforward: do it with a clinician who knows your cancer and metabolic history and can run baseline and follow-up IGF-1 and glucose, insist on a real certificate of analysis for the exact batch from a pharmacy or licensed channel rather than a research-chemical vendor, and understand that for any goal other than HIV-associated lipodystrophy you are outside the evidence and the result will reverse when you stop. And if the honest answer for your situation is "not worth it," that is a legitimate place to land.

What the evidence implies clinically

By Dr. Sam Walters, NMD, Medical Director

Tesamorelin is the one peptide in this group I can describe without immediately reaching for a caveat about missing trials, and that is exactly why it needs a careful one. The evidence for its approved use is genuine: it reduces visceral fat in HIV-associated lipodystrophy, repeatedly, in proper randomized trials, and an FDA approval and a recent meta-analysis stand behind it. If the question is that specific clinical problem, this is real medicine with a real evidence base, and it should be evaluated as such with a clinician who manages it.

The trouble is that almost no one asking about tesamorelin is asking about HIV lipodystrophy. They are asking about belly fat, aging, and recomposition, and for those the picture is very different: the controlled data outside HIV are limited to a few selected research groups, the general-population and performance uses have no trial at all, the benefit reverses the moment treatment stops, and the label that approves the drug also warns about IGF-1, glucose, and tumor growth and says outright that it is not for weight loss. The fact that a drug is approved for one thing is not evidence it is safe or effective for another, and a growth-promoting signal is not something I would raise casually in anyone with a cancer history. The reasonable reading for most people considering it off-label is caution and a frank conversation with their own prescriber about whether the unproven upside is worth the known and unknown risks. That is the conversation I would want them to have before deciding.

The honest close

For tesamorelin, the evidence supports an honest and unusually favorable description for one use, and a cautious one for every other. In HIV-associated lipodystrophy it genuinely reduces visceral fat, by roughly fifteen to eighteen percent, in replicated Phase-3 trials, with an FDA approval and a 2026 meta-analysis behind it, and it improves lipids and body image; that is real, and it is the example of what approved and evidenced looks like. But the effect reverses when treatment stops, the approval is for that disease and not for weight loss, the controlled evidence outside HIV is limited to a few selected groups, the general-population and performance uses have no trial at all, and the label warns about IGF-1, glucose, and tumor growth. For the approved indication, the read is "this is real medicine, weigh it with your specialist." For the off-label uses that drive most of the demand, the accurate read is "promising by mechanism, unproven in people like you, and not without real cautions," and for athletes it is "banned and detectable."

We do not prescribe, and we do not recommend a dose for you. We report what is actually approved, what is genuinely shown, and what people and clinics do beyond it, and we synthesize the evidence so you can have an informed conversation with your clinician, including when the honest read is "this is approved for a condition you don't have."

This content is for informational purposes only, is not medical advice, and creates no doctor–patient relationship. Consult a licensed practitioner before changing any therapeutic protocol.

We don’t prescribe. We synthesize the research so you can have an informed conversation with your prescriber. And if the honest read of the evidence is “not yet” or “probably not worth it for you” — we’ll tell you that too.